Drugs & Side Effects | COX-2 / Arthritis

Vioxx News

Investment Analyst Rates Merck Stock "Neutral"

RSS News Feeds
Drugs & Pharmacuticals
Stroke
Vioxx
 All RSS Feeds

At a glance:

Merck can handle the financial hit from the Vioxx lawsuits because of large cash reserves, according to UBS Investment Research. 
 
This investment analyst rates Merck stock "neutral" for now, pending further outcomes. It is expected that the Vioxx lawsuits will take many years to resolve and that Merck can weather the storm.

Merck's Vioxx Liability Appears 'Manageable'

Forbes - 4/24/2006 5:38 PM

UBS Investment Research maintained a "neutral" rating on Merck after the drug company lost another Vioxx-related court battle last Friday.
 
Last week, a Texas jury ordered Merck to pay $32 million in damages to the family of a 71-year-old man who died of a heart attack in April 2001. Merck said in a statement it will appeal the verdict.
 
· Read The Full Vioxx Article From Forbes -->

· Read All Vioxx (Rofecoxib) News Stories -->

Comments On Vioxx News Articles:


No Current Comments
Posted by Admin on 3/20/2006

There are no current comments. Why not post one?

Leave a Comment:

Once you click the 'Save Comment' button, you will receive a verification email from our website. Be sure to change any spam settings to allow webmaster@lawsuitsearch.com as a trusted sender.
 
If you are already a member, you can Sign In Here.
 
You can create your own FREE user account that you can use to participate in our message boards, blogs, newsletters and other community activities such as this one. To get your FREE user account, click here.

Email Address:

Your Name:

Message Title:

Message: